Safety and Effectiveness of Delamanid-containing Regimen for Treatment of Patients With Multidrug-resistant Tuberculosis in China
试验速览
- 阶段
- 4 期
- 发起方
- 入组人数
- 608
- 试验地点
- 25
- 主要终点
- Proportion of participants experiencing treatment-emergent AEs
研究概览
简要总结
The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB.
详细描述
This is a single-arm, multicenter, phase #, open-label trial to evaluate the safety and effectiveness of delamanid-containing regimen in men and women aged 18 to 65 years with microbiologically confirmed pulmonary MDR-TB in China. A target of 600 participants will be enrolled. The study will consist of a screening phase of up to 8 weeks, an open-label study treatment phase of 13-20 months, and a follow-up phase of 12-month after end of study treatment. During the study treatment phase, participants will receive an MDR-TB regimen consisting of 24 weeks of delamanid in combination with 13-20 months of a background regimen.
Participants will be instructed to take their assigned dose of delamanid with at least 3 additional probably effective background drugs according to national and international guidelines. Delamanid dosage will be 100 mg twice daily (b.i.d.) for 24 weeks.
Safety evaluations will include monitoring of AEs, visual acuity testing, routine blood examinations (such as hematology, clinical chemistry, HIV, TSH [for subjects receiving PTO] measurements), urinalysis, and electrocardiograms (ECGs). Participants will initiate treatment with the study regimen if they meet the study eligibility criteria.The end of study will be considered as the last contact for the last participant in the study.
A participant will be considered to have completed the study if he or she has completed the 13-20 months study treatment phase and the required post-treatment follow-up phase. Participants who prematurely discontinue study treatment (unless they withdraw consent) will be followed up for 12 months after end of delamanid treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with microbiologically confirmed multidrug-resistant/rifampicin resistant tuberculosis ;
- •Age 18 to 65 years old;
- •MDR-TB treatment has not been started, or treatment has been started but treatment regimen need to be intensified;
- •According to the guidelines of WHO's consolidated guidelines for the treatment of drug-resistant TB and the consensus of Chinese experts in the treatment of multidrug-resistant and rifampicin resistant TB (2019 edition), effective treatment regimens can only be formed by adding Delamanid based on the results of drug susceptibility testing and the previous treatment history;
- •No history of respiratory failure, no history of cardiac dysfunction and clinically significant arrhythmia, QTcF < 450ms;
- •Patients should be able to take medicines and clinical monitoring according to the requirements of the trial during the treatment and follow-up phases, and adverse effects should be reported to the responsible doctor timely ;
- •Patients should sign the informed consent.
排除标准
- •A history of allergy to nitroimidazole and pyrrole drugs such as Delamanid, metronidazole, tinidazole, or any excipient.
- •Serum transaminase increased ≥3 times the upper limit of normal value or total bilirubin increased ≥2.5 times the upper limit of normal, serum albumin <2.8 g / dL, severe renal impairment.
- •Taking strong CYP3A4 inducer drugs (such as carbamazepine).
- •Is known to be pregnant (or planning to become pregnant) .
- •Participants took part in trials of other new unlisted drugs within the past three months;
- •Congenital QT interval prolongation is known or has any disease that may prolong the QT interval or QTc no less than 500 ms;
- •A history of symptomatic arrhythmia or suffering from clinically related bradycardia;
- •Any cardiac disease that can induce arrhythmias, such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy), or congestive heart failure with reduced left ventricular ejection fraction;
- •Electrolyte disturbance, especially hypokalemia, hypocalcemia or hypomagnesemia;
- •Taking drugs known to prolong the QT interval such as the following drugs (but not limited to) :
- •① Anti-arrhythmic drugs, such as amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol, etc .;
- •Antipsychotic drugs, such as phenothiazine, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide or thioridazine, and antidepressants; ③ Certain antibiotics, including:
- •Macrolides, such as erythromycin, clarithromycin, etc ;
- •Moxifloxacin, Sparfloxacin;
- •Triazole antifungal drugs;
- •Spray him with amidine;
- •Saquinavir;
- •④ Some non-sedative antihistamines, such as terfenadine, astemizole, mizolastine, etc.
- •Other drugs with protential cardiac risk : cisapride, haloperidol, domperidone, bepridil, diphemanil, probucol, dimepheptanol, methadone, vinblastine, arsenic trioxide.
- •Deletion criteria:
- •Those who are found to have exclusion items after enrolled;
- •Serious adverse reactions caused by Delamanid, such as allergic reactions, mental disorders, and liver injury (transaminases increase greater than 3 times the upper limit of normal value or total bilirubin increase greater than 2.5 times the upper limit of normal);
- •QTcF ≥500ms or clinically significant ventricular arrhythmia is confirmed;
- •The expert group made decision that it is not appropriate for the patient to continue the treatment with Delamanid;
- •The patient cannot tolerate the background treatment regimen, or the modified background treatment regimen cannot meet the 3 definitive sensitive drugs or 4 probably sensitive drugs;
- •The patient requests dropout.
研究组 & 干预措施
delamanid containing regimen arm
the only one arm to be studied with delamid-containing regimen.
干预措施: Delamanid (Drug)
结局指标
主要结局
Proportion of participants experiencing treatment-emergent AEs
时间窗: the whole treatment phase,an average of 18-20 months
the percentage of participants who experienced adverse effect during treatment phase.
Proportion of participants experiencing all-cause mortality
时间窗: from enrollment to the completion of the trial ,an average of 30-32months
the percentage of participants who died during the trial.
次要结局
- The Percentage of Participants With Sputum Culture Conversion(up to 24 weeks after enrollment)
- The Median Time to Sputum Culture Conversion(upto 24 weeks after enrollment)
研究者
Liang Li
Vice president
Beijing Chest Hospital